206 related articles for article (PubMed ID: 36031930)
1. Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates.
Tukhvatulin AI; Gordeychuk IV; Dolzhikova IV; Dzharullaeva AS; Krasina ME; Bayurova EO; Grousova DM; Kovyrshina AV; Kondrashova AS; Avdoshina DV; Gulyaev SA; Gulyaeva TV; Moroz AV; Illarionova VV; Zorkov ID; Iliukhina AA; Shelkov AY; Botikov AG; Erokhova AS; Shcheblyakov DV; Esmagambetov IB; Zubkova OV; Tokarskaya EA; Savina DM; Vereveyko YR; Ungur AS; Naroditsky BS; Ishmukhametov AA; Logunov DY; Gintsburg AL
Emerg Microbes Infect; 2022 Dec; 11(1):2229-2247. PubMed ID: 36031930
[TBL] [Abstract][Full Text] [Related]
2. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():995235. PubMed ID: 36172368
[TBL] [Abstract][Full Text] [Related]
3. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
[TBL] [Abstract][Full Text] [Related]
4. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
5. Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study.
Yegorov S; Kadyrova I; Negmetzhanov B; Kolesnikova Y; Kolesnichenko S; Korshukov I; Baiken Y; Matkarimov B; Miller MS; Hortelano GH; Babenko D
Sci Rep; 2022 Aug; 12(1):13207. PubMed ID: 35915123
[TBL] [Abstract][Full Text] [Related]
6. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
Americo JL; Cotter CA; Earl PL; Liu R; Moss B
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
[TBL] [Abstract][Full Text] [Related]
7. Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
Hemmi T; Ainai A; Hashiguchi T; Tobiume M; Kanno T; Iwata-Yoshikawa N; Iida S; Sato Y; Miyamoto S; Ueno A; Sano K; Saito S; Shiwa-Sudo N; Nagata N; Tamura K; Suzuki R; Hasegawa H; Suzuki T
Vaccine; 2022 Sep; 40(41):5892-5903. PubMed ID: 36064667
[TBL] [Abstract][Full Text] [Related]
8. Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern.
Rudi E; Martin Aispuro P; Zurita E; Gonzalez Lopez Ledesma MM; Bottero D; Malito J; Gabrielli M; Gaillard E; Stuible M; Durocher Y; Gamarnik AV; Wigdorovitz A; Hozbor D
Front Immunol; 2022; 13():1020159. PubMed ID: 36248791
[TBL] [Abstract][Full Text] [Related]
9. Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines.
Adjobimey T; Meyer J; Sollberg L; Bawolt M; Berens C; Kovačević P; Trudić A; Parcina M; Hoerauf A
Front Immunol; 2022; 13():917905. PubMed ID: 35799790
[TBL] [Abstract][Full Text] [Related]
10. Heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis.
Pereson MJ; Amaya L; Neukam K; Baré P; Echegoyen N; Badano MN; Lucero A; Martelli A; Garcia GH; Videla C; Martínez AP; Di Lello FA
Clin Microbiol Infect; 2022 Oct; 28(10):1382-1388. PubMed ID: 35595128
[TBL] [Abstract][Full Text] [Related]
11. The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.
Del Fresno C; García-Arriaza J; Martínez-Cano S; Heras-Murillo I; Jarit-Cabanillas A; Amores-Iniesta J; Brandi P; Dunphy G; Suay-Corredera C; Pricolo MR; Vicente N; López-Perrote A; Cabezudo S; González-Corpas A; Llorca O; Alegre-Cebollada J; Garaigorta U; Gastaminza P; Esteban M; Sancho D
Front Immunol; 2021; 12():748103. PubMed ID: 34867974
[TBL] [Abstract][Full Text] [Related]
12. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
14. Functional Profiling of In Vitro Reactivated Memory B Cells Following Natural SARS-CoV-2 Infection and Gam-COVID-Vac Vaccination.
Astakhova EA; Byazrova MG; Yusubalieva GM; Kulemzin SV; Kruglova NA; Prilipov AG; Baklaushev VP; Gorchakov AA; Taranin AV; Filatov AV
Cells; 2022 Jun; 11(13):. PubMed ID: 35805076
[TBL] [Abstract][Full Text] [Related]
15. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
Nagai M; Moriyama M; Ichinohe T
mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
[TBL] [Abstract][Full Text] [Related]
16. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
[TBL] [Abstract][Full Text] [Related]
17. Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level.
Godkov MA; Ogarkova DA; Gushchin VA; Kleymenov DA; Mazunina EP; Bykonia EN; Pochtovyi AA; Shustov VV; Shcheblyakov DV; Komarov AG; Tsibin AN; Zlobin VI; Logunov DY; Gintsburg AL
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679936
[TBL] [Abstract][Full Text] [Related]
18. ChAdOx1-S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination.
Cokarić Brdovčak M; Materljan J; Šustić M; Ravlić S; Ružić T; Lisnić B; Miklić K; Brizić I; Pribanić Matešić M; Juranić Lisnić V; Halassy B; Rončević D; Knežević Z; Štefan L; Bertoglio F; Schubert M; Čičin-Šain L; Markotić A; Jonjić S; Krmpotić A
Eur J Immunol; 2022 Jun; 52(6):936-945. PubMed ID: 35304741
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort.
Blanco S; Salomé Konigheim B; Diaz A; Spinsanti L; Javier Aguilar J; Elisa Rivarola M; Beranek M; Collino C; MinSalCba Working Group ; Fcm-Unc Working Group ; Diaz M; Gabriela Barbás M; Mangeaud A; Verónica Gallego S
Vaccine; 2022 Jan; 40(5):811-818. PubMed ID: 34953609
[TBL] [Abstract][Full Text] [Related]
20. Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon
Byazrova MG; Kulemzin SV; Astakhova EA; Belovezhets TN; Efimov GA; Chikaev AN; Kolotygin IO; Gorchakov AA; Taranin AV; Filatov AV
Front Immunol; 2022; 13():840707. PubMed ID: 35280987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
